No significant survival difference between consolidative and delayed thoracic RT in extensive-stage SCLC

Among 307 patients with extensive-stage SCLC, overall survival did not significantly differ between consolidative and progression-triggered thoracic RT, including after matching.

KEY POINTS

  • This retrospective multicenter study from three Chinese cancer centers included 307 patients with extensive-stage small cell lung cancer (ES-SCLC) who received thoracic radiotherapy (TRT) after first-line chemotherapy with or without immune checkpoint inhibitors between January 2018 and April 2024. 207 patients received consolidative TRT (cTRT) without preceding progression, while 100 received delayed TRT (dTRT) after locoregional progression or tumor enlargement. A predefined immunotherapy-treated subgroup included 130 patients, comprising 80 receiving cTRT and 50 receiving dTRT. Propensity score matching (PSM) generated 100 matched pairs in the full cohort and 50 matched pairs in the immunotherapy subgroup.
  • Treatment groups differed by disease behavior, not simply by the interval between systemic therapy and irradiation. cTRT was administered to patients with at least stable disease after first-line treatment, whereas dTRT was triggered by local tumor or nodal progression before second-line systemic therapy. Median time from completion of first-line treatment to TRT was 32 versus 61 days in the full cohort (p<0.001) and 31 versus 72 days in the immunotherapy subgroup (p<0.001). Radiotherapy prescriptions varied substantially, including 45 Gy in 30 twice-daily fractions, 60 Gy in 30 fractions, 45 Gy in 15 fractions, and 30 Gy in 10 fractions, with selected patients receiving SBRT.
  • Overall survival, the primary endpoint, did not differ significantly between strategies. Before matching, median OS was 19.83 months with cTRT versus 17.77 months with dTRT (p=0.15). After PSM, median OS was 17.17 versus 17.77 months (p=0.68), respectively. Multivariable Cox regression also showed no statistically significant association between TRT strategy and survival (adjusted HR 0.82, 95% CI 0.60–1.14; p=0.24). In the immunotherapy-treated subgroup, matched median OS was 23.30 versus 16.83 months (p=0.30), with adjusted HR 0.79 (95% CI 0.49–1.30; p=0.35). These findings do not establish equivalence or noninferiority of delayed treatment.
  • Exploratory progression-free survival favored consolidative TRT, but its endpoint definition creates important interpretive limitations. Following PSM, median progression-free survival from diagnosis to post-radiotherapy recurrence (PFS-DR) was 8.70 versus 6.30 months in the full cohort and 8.57 versus 6.63 months in the immunotherapy subgroup (both p<0.0001). Multivariable analyses associated cTRT with lower PFS-DR event hazards in the full cohort (adjusted HR 0.35, 95% CI 0.25–0.48) and immunotherapy subgroup (adjusted HR 0.36, 95% CI 0.22–0.58). Crucially, the progression that triggered delayed TRT was not counted as an event, although the endpoint was measured from initial diagnosis. PFS-DR therefore cannot be interpreted as conventional progression-free survival or an unbiased estimate of treatment-timing benefit.
  • Reported local control favored earlier irradiation, although the populations were clinically distinct. In the full cohort, six-month local control was 95.6% after cTRT versus 85.4% after dTRT, while 12-month local control was 78.8% versus 32.5% (p<0.0001). Similar differences appeared in the immunotherapy subgroup, with 12-month local control of 75.6% versus 22.7% (p=0.002). Patients receiving dTRT had larger tumors at irradiation: among patients with measured pretreatment volumes, median GTV was 71.86 versus 37.27 cm³ for delayed versus consolidative TRT (p=0.0004). Patients receiving cTRT also had higher initial response rates (84.5% vs 69.0%) and were more likely to have received prophylactic cranial irradiation (26.6% vs 7.0%), complicating interpretation of the local control differences.
  • Severe radiation-related toxicity was uncommon, but grade 2 pneumonitis was more frequent with consolidation. Across the full cohort, grade 2 radiation pneumonitis occurred in 11.1% with cTRT versus 4.0% with dTRT, contributing to a significant difference in pneumonitis grade distribution (p=0.031). Four patients (1.3% of the full cohort) developed grade 3 pneumonitis, all after cTRT, and recovered with corticosteroids. Grade 3 radiation esophagitis occurred in 0.7%, with no reported grade 4–5 radiation pneumonitis or esophagitis and no treatment-related deaths. In the immunotherapy subgroup, grade 2 pneumonitis occurred in 10.0% versus 6.0%, without a statistically significant difference in overall pneumonitis grade distribution.
  • The study cannot establish that deferring thoracic irradiation until progression is clinically equivalent to consolidation. All included patients eventually received TRT, excluding those who progressed rapidly, deteriorated, or died without undergoing irradiation. Group allocation depended on treatment response and progression, creating selection and potential immortal-time biases that propensity matching cannot fully resolve. Moreover, substantial dosimetric data were missing, with esophageal dose parameters available for only about 41% of patients, and missing values were imputed for matching and regression. The heterogeneous systemic regimens, lack of centralized imaging review, relatively small matched immunotherapy subgroup, and absence of randomization further limit conclusions about optimal TRT timing.

CLINICAL TAKEAWAY

In this multicenter observational cohort of patients with ES-SCLC who ultimately received thoracic radiotherapy, consolidative and progression-triggered treatment were not associated with statistically different overall survival, while earlier irradiation showed more favorable reported local control and exploratory PFS-DR. However, the two strategies were defined by different disease trajectories, and the unconventional progression endpoint introduces substantial bias. These findings are hypothesis-generating and do not establish that delaying consolidative thoracic radiotherapy until progression is a safe or equivalent strategy.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction